Sano Healthcare announced that the GhunterRevascularizationDevice intracranial embolization stent independently developed by the company's holding subsidiary Sano Shenchang recently received registration approval from the Turkish Ministry of Health. This product is used to remove blood clots in large intracranial blood vessels and restore blood flow in ischemic stroke patients. It was registered by the State Drug Administration in April 2023 and certified by the European Union CEMDR in February 2026. This approval is the first time that Sano Shenchang products have passed a registration application in Turkey. It will play a positive role in the promotion and sale of the company's products in the corresponding market, but it is still impossible to predict the impact on specific performance due to factors such as regulatory policies, market environment, and exchange rate fluctuations.

Sano Healthcare announced that the GhunterRevascularizationDevice intracranial embolization stent independently developed by the company's holding subsidiary Sano Shenchang recently received registration approval from the Turkish Ministry of Health. This product is used to remove blood clots in large intracranial blood vessels and restore blood flow in ischemic stroke patients. It was registered by the State Drug Administration in April 2023 and certified by the European Union CEMDR in February 2026. This approval is the first time that Sano Shenchang products have passed a registration application in Turkey. It will play a positive role in the promotion and sale of the company's products in the corresponding market, but it is still impossible to predict the impact on specific performance due to factors such as regulatory policies, market environment, and exchange rate fluctuations.